Investigating how mitochondrial protein translation affects cell survival
Official title: Mitoribosome protein translation signaling and survival mechanisms
Funded at Dana-Farber Cancer Inst · NIH-11126750 · Data updated 2026-11-12
This study is looking at how problems with tiny parts of our cells called mitochondria can cause cell damage, especially when we're under stress, and it's testing certain antibiotics to see if they can help protect our cells from this damage, which could lead to new treatments for mitochondrial diseases and issues related to aging.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 30, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $712,792 |
| NIH project number | 5R01AG086369-03 |
| Project ID | NIH-11126750 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with mitochondrial diseases, neurodegenerative conditions, or age-related impairments.
✕Less likely to help
Patients with non-mitochondrial related diseases or those without any mitochondrial dysfunction may not benefit from this research.
What this research studies
This research focuses on understanding the role of mitochondrial function in cell survival, particularly under stress conditions. It explores how mitochondrial dysfunction, which can occur due to genetic mutations or aging, leads to cellular damage and death. The study employs high-throughput screening of antibiotics, specifically tetracyclines, to identify compounds that can protect cells from damage by targeting the mitoribosome protein translation. By examining these mechanisms, the research aims to uncover potential therapeutic strategies for mitochondrial diseases and age-related conditions.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve cell survival in patients with mitochondrial diseases and age-related disorders.
How similar studies have gone: Previous research has shown promise in using antibiotics like tetracyclines to target mitochondrial dysfunction, indicating a potential for success in this approach.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Puigserver, Pere — Dana-Farber Cancer Inst
- Study coordinator: Puigserver, Pere
Related research
Other NIH-funded projects on the same topics.
-
Helping young people with cancer understand their genetic risks
This study is creating a special program to help teenagers and young adults with hereditary cancer risks learn about their health and make smart choices, while also supporting their families along the way.
-
Core administrative hub for a multifaceted cancer center program
A large, international cancer research program at Dana-Farber aims to advance a curative strategy for multiple myeloma by coordinating translational research, clinical trials, and data analysis.
-
Automated, interactive lab tool to define radiation targets in cancer care
Aims to make it easier and safer to outline the area to treat in radiation therapy for cancers by using smart software and a patient-friendly interface.
-
Cancer Atlas Network data hub to share big cancer data
A national project helps researchers store, harmonize, and share large cancer data collections so doctors and scientists can learn from many patients.
-
Bridge-building cancer research partnership for education, outreach, and science
A joint effort between UMass Boston and Harvard Cancer Consortium to accelerate cancer research and education by connecting lower-resourced institutions with a leading cancer center.
-
NexTGen: Next-Generation T cell therapy for childhood cancers
A charity-friendly overview: researchers at Dana-Farber are developing advanced engineered T-cell therapies to treat pediatric solid cancers like brain tumors and sarcomas.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.